Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free CTX Stock Alerts

Crescita Therapeutics (CTX) Competitors

Crescita Therapeutics logo
C$0.76 0.00 (0.00%)
As of 12:35 PM Eastern
Compare

CTX vs. HEXO, LABS, VIR, ZOM, and META

Should you be buying Crescita Therapeutics stock or one of its competitors? The main competitors of Crescita Therapeutics include HEXO (HEXO), MediPharm Labs (LABS), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), and Meta Growth (META). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Crescita Therapeutics compare to HEXO?

Crescita Therapeutics (TSE:CTX) and HEXO (TSE:HEXO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

In the previous week, Crescita Therapeutics' average media sentiment score of 0.00 equaled HEXO'saverage media sentiment score.

Company Overall Sentiment
Crescita Therapeutics Neutral
HEXO Neutral

Crescita Therapeutics has a beta of -1.339634, meaning that its share price is 234% less volatile than the S&P 500. Comparatively, HEXO has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500.

3.1% of Crescita Therapeutics shares are held by institutional investors. Comparatively, 7.6% of HEXO shares are held by institutional investors. 10.9% of Crescita Therapeutics shares are held by insiders. Comparatively, 3.0% of HEXO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Crescita Therapeutics has a net margin of -0.44% compared to HEXO's net margin of -220.13%. Crescita Therapeutics' return on equity of -0.59% beat HEXO's return on equity.

Company Net Margins Return on Equity Return on Assets
Crescita Therapeutics-0.44% -0.59% -8.26%
HEXO -220.13%-106.39%-14.96%

Crescita Therapeutics has higher earnings, but lower revenue than HEXO.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$21.12M0.67-C$2.61MN/AN/A
HEXOC$124.10M0.00-C$273.18M-C$3.41N/A

Summary

Crescita Therapeutics beats HEXO on 6 of the 9 factors compared between the two stocks.

How does Crescita Therapeutics compare to MediPharm Labs?

Crescita Therapeutics (TSE:CTX) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Crescita Therapeutics has a beta of -1.339634, meaning that its stock price is 234% less volatile than the S&P 500. Comparatively, MediPharm Labs has a beta of -0.383492, meaning that its stock price is 138% less volatile than the S&P 500.

Crescita Therapeutics has higher earnings, but lower revenue than MediPharm Labs.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$21.12M0.67-C$2.61MN/AN/A
MediPharm LabsC$45.12M0.80-C$12.05M-C$0.02N/A

3.1% of Crescita Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of MediPharm Labs shares are owned by institutional investors. 10.9% of Crescita Therapeutics shares are owned by insiders. Comparatively, 4.5% of MediPharm Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Crescita Therapeutics has a net margin of -0.44% compared to MediPharm Labs' net margin of -18.32%. Crescita Therapeutics' return on equity of -0.59% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Crescita Therapeutics-0.44% -0.59% -8.26%
MediPharm Labs -18.32%-21.10%-7.17%

In the previous week, Crescita Therapeutics' average media sentiment score of 0.00 equaled MediPharm Labs'average media sentiment score.

Company Overall Sentiment
Crescita Therapeutics Neutral
MediPharm Labs Neutral

Summary

Crescita Therapeutics beats MediPharm Labs on 6 of the 10 factors compared between the two stocks.

How does Crescita Therapeutics compare to Viridium Pacific Group?

Crescita Therapeutics (TSE:CTX) and Viridium Pacific Group (CVE:VIR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Viridium Pacific Group has a net margin of 0.00% compared to Crescita Therapeutics' net margin of -0.44%. Viridium Pacific Group's return on equity of 0.00% beat Crescita Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Crescita Therapeutics-0.44% -0.59% -8.26%
Viridium Pacific Group N/A N/A N/A

Crescita Therapeutics has higher revenue and earnings than Viridium Pacific Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$21.12M0.67-C$2.61MN/AN/A
Viridium Pacific GroupC$1.09M34.46-C$12.64M-C$0.13N/A

In the previous week, Crescita Therapeutics' average media sentiment score of 0.00 equaled Viridium Pacific Group'saverage media sentiment score.

Company Overall Sentiment
Crescita Therapeutics Neutral
Viridium Pacific Group Neutral

3.1% of Crescita Therapeutics shares are held by institutional investors. 10.9% of Crescita Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Crescita Therapeutics beats Viridium Pacific Group on 5 of the 9 factors compared between the two stocks.

How does Crescita Therapeutics compare to Zomedica Pharmaceuticals Corp. (ZOM.V)?

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

3.1% of Crescita Therapeutics shares are held by institutional investors. 10.9% of Crescita Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zomedica Pharmaceuticals Corp. (ZOM.V) has a net margin of 0.00% compared to Crescita Therapeutics' net margin of -0.44%. Zomedica Pharmaceuticals Corp. (ZOM.V)'s return on equity of 0.00% beat Crescita Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zomedica Pharmaceuticals Corp. (ZOM.V)N/A N/A N/A
Crescita Therapeutics -0.44%-0.59%-8.26%

Zomedica Pharmaceuticals Corp. (ZOM.V) has higher earnings, but lower revenue than Crescita Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zomedica Pharmaceuticals Corp. (ZOM.V)N/AN/AN/A-C$0.11N/A
Crescita TherapeuticsC$21.12M0.67-C$2.61MN/AN/A

In the previous week, Zomedica Pharmaceuticals Corp. (ZOM.V)'s average media sentiment score of 0.00 equaled Crescita Therapeutics'average media sentiment score.

Company Overall Sentiment
Zomedica Pharmaceuticals Corp. (ZOM.V) Neutral
Crescita Therapeutics Neutral

Summary

Crescita Therapeutics beats Zomedica Pharmaceuticals Corp. (ZOM.V) on 4 of the 7 factors compared between the two stocks.

How does Crescita Therapeutics compare to Meta Growth?

Meta Growth (CVE:META) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

3.1% of Crescita Therapeutics shares are owned by institutional investors. 10.9% of Crescita Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Meta Growth has a net margin of 0.00% compared to Crescita Therapeutics' net margin of -0.44%. Meta Growth's return on equity of 0.00% beat Crescita Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Meta GrowthN/A N/A N/A
Crescita Therapeutics -0.44%-0.59%-8.26%

Crescita Therapeutics has lower revenue, but higher earnings than Meta Growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Meta GrowthC$60.96M0.54-C$50.41M-C$0.21N/A
Crescita TherapeuticsC$21.12M0.67-C$2.61MN/AN/A

In the previous week, Meta Growth had 9 more articles in the media than Crescita Therapeutics. MarketBeat recorded 9 mentions for Meta Growth and 0 mentions for Crescita Therapeutics. Meta Growth's average media sentiment score of 0.45 beat Crescita Therapeutics' score of 0.00 indicating that Meta Growth is being referred to more favorably in the media.

Company Overall Sentiment
Meta Growth Neutral
Crescita Therapeutics Neutral

Summary

Meta Growth beats Crescita Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Crescita Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTX vs. The Competition

Export
MetricCrescita TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$14.15MC$1.62BC$6.25BC$11.72B
Dividend YieldN/A2.97%2.74%6.22%
P/E Ratio37.504.1824.9123.83
Price / Sales0.671,488.53504.5613.46
Price / Cash1.2010.3743.3082.69
Price / Book0.9110.729.674.48
Net Income-C$2.61MC$21.15BC$3.55BC$300.68M
7 Day Performance1.33%-1.16%1.70%0.12%
1 Month Performance2.70%0.17%5.62%2.88%
1 Year Performance38.18%24.19%34.42%57.78%

Crescita Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTX
Crescita Therapeutics
N/AC$0.76
flat		N/AN/AC$14.15MC$21.12M37.5062
HEXO
HEXO
N/AN/AN/AN/AC$38.72MC$124.10MN/A690
LABS
MediPharm Labs
N/AC$0.09
flat		N/AN/AC$38.24MC$45.12MN/A130
VIR
Viridium Pacific Group
N/AC$0.38
+5.6%		N/AN/AC$37.52MC$1.09MN/A580
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
N/AC$0.29
-6.6%		N/AN/AC$36.73MN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:CTX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel